Applied Therapeutics (APLT) Set to Announce Earnings on Monday

Applied Therapeutics (NASDAQ:APLT – Get Rating) will be posting its quarterly earnings results on Monday, March 20th.

Applied Therapeutics Trading Up 5.5 %

Applied Therapeutics stock opened at $0.95 on Friday. The stock has a market cap of $45.76 million, a P/E ratio of -0.29 and a beta of 1.90. The stock has a 50 day moving average of $1.02 and a 200-day moving average of $0.95. Applied Therapeutics has a 52 week low of $0.50 and a 52 week high of $2.73.

Hedge Funds Weigh In On Applied Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in APLT. Acadian Asset Management LLC purchased a new position in shares of Applied Therapeutics during the 1st quarter valued at approximately $70,000. BlackRock Inc. boosted its stake in shares of Applied Therapeutics by 5.0% during the 1st quarter. BlackRock Inc. now owns 1,363,403 shares of the company’s stock valued at $2,876,000 after buying an additional 64,872 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Applied Therapeutics by 1,503.4% during the 1st quarter. Renaissance Technologies LLC now owns 282,200 shares of the company’s stock valued at $595,000 after buying an additional 264,600 shares during the last quarter. State Street Corp lifted its stake in Applied Therapeutics by 24.8% during the first quarter. State Street Corp now owns 426,404 shares of the company’s stock worth $900,000 after purchasing an additional 84,753 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in Applied Therapeutics by 25.4% during the first quarter. Goldman Sachs Group Inc. now owns 94,664 shares of the company’s stock worth $200,000 after purchasing an additional 19,159 shares during the last quarter. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

About Applied Therapeutics

(Get Rating)

Applied Therapeutics, Inc is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.